Pliant Therapeutics (STU:9PT) Margin of Safety % (DCF FCF Based): N/A (As of Jul. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:9PT Pliant Therapeutics Inc STU:9PT
35 GF Score
Price €0.94
GF Value €0.38
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Pliant Therapeutics Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Pliant Therapeutics's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

STU:9PT vs BYSI, MCRB, XBIT: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, Pliant Therapeutics's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pliant Therapeutics Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pliant Therapeutics's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Pliant Therapeutics's Margin of Safety % (DCF FCF Based) falls into.


STU:9PT
35GF Score
Pliant Therapeutics Inc STU:9PT
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Pliant Therapeutics (STU:9PT) Overvalued in 2026?

Based on GuruFocus' analysis, Pliant Therapeutics stock appears to be overvalued. The current stock price of €0.94 is trading 146.2% above its estimated GF Value™ of €0.38. GuruFocus considers Pliant Therapeutics to be Significantly Overvalued.

Key valuation signals for STU:9PT:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: €0.38 vs. price of €0.94 (146.2% above fair value)
  • GF Score™: 35/100 with 2 warning signs

No single metric tells the full story. See the STU:9PT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pliant Therapeutics Business Description

Other Exchanges PLRX:USA
Address 331 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.
35GF Score

Get the complete analysis for STU:9PT

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.94
Price
€0.38
GF Value